Compare Incyte Corporation (INCY) vs Direxion Daily FTSE China Bull 3x Shares (YINN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Direxion Daily FTSE China Bull 3x Shares — how do they compare? Incyte Corporation trades at $112.77 (market cap $22.85B), while Direxion Daily FTSE China Bull 3x Shares trades at $25.22 (market cap $560.32M). The key difference: Incyte Corporation is far larger — about 40.8× Direxion Daily FTSE China Bull 3x Shares's market cap, and Incyte Corporation is trading nearer its 52-week high, Direxion Daily FTSE China Bull 3x Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Direxion Daily FTSE China Bull 3x Shares for 25 Days on average.
| INCY | YINN | |
|---|---|---|
Market Cap | $22.85B | $560.32M |
Volume | 1,927,029 | 1,009,521 |
Sector | Health | Leveraged / Inverse |
52-Week High | $129.93 | $52.69 |
52-Week Low | $83.80 | $21.45 |
Typical Hold Time | 33 Days | 25 Days |
Enterprise Value | $18.35B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $113.61, up 0.15% on the day, with a mixed technical signal leaning bearish. The company reported strong 2025 results with revenue of $5.14B and net income of $1.29B, and recent earnings beats in Q1 and Q2 2026. Key developments include FDA approval for Atebrioz and a strategic focus on post-JAKAFI growth targeting $4B in non-JAKAFI sales by 2029.
The outlook is cautiously optimistic, supported by robust profitability and pipeline progress, but tempered by near-term earnings pressure and technical weakness. Risks include JAKAFI's patent expiration after 2029 and competitive threats. Analysts maintain a Buy consensus with a $132.43 price target, implying significant upside from current levels.
YINN trades at $25.17, up 6.83% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The stock lacks fundamental financial data disclosure, with key valuation and profitability ratios unavailable. Recent news highlights China's economic policies and export controls, which may influence the fund's underlying holdings.
The outlook is cautious due to bearish technicals and opaque fundamentals. Risks include exposure to Chinese market volatility and regulatory changes. Analyst sentiment is not clearly defined without current consensus data, requiring careful monitoring of emerging financial disclosures and geopolitical developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Direxion Daily FTSE China Bull 3x Shares
YINN is a leveraged ETF that seeks daily investment results, before fees and expenses, of 300% (3x) of the daily performance of the FTSE China 50 Index. It is a tactical instrument designed for sophisticated traders seeking to magnify short-term bullish views on large-cap Chinese equities, primarily those trading on the Hong Kong Stock Exchange.
Read more on YINN →
